Evidence map›Paper›PMID 40391159›Full record

ArticleFrontiers in oncology2025

Efficacy and safety of low-dose X-rays based intraoperative radiotherapy for high-grade gliomas: a single-center retrospective study.

Zhongcheng Wen, Jun Liu, Yang Bai, Minghao Zhou, Jiajie He, Ying Xu, Ying Yan, Fuyong Li, Shun Gong, Jianan Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhongcheng Wen *Department of Neurosurgery, General Hospital of Northern Theater Command, Postgraduate Training Base of Dalian Medical University, Shenyang, China.
Jun Liu *Department of Neurosurgery, General Hospital of Northern Theater Command, Postgraduate Training Base of Dalian Medical University, Shenyang, China.
Yang BaiDepartment of Neurosurgery, General Hospital of Northern Theater Command, Postgraduate Training Base of Dalian Medical University, Shenyang, China.
Minghao ZhouDepartment of Neurosurgery, General Hospital of Northern Theater Command, Postgraduate Training Base of Dalian Medical University, Shenyang, China.
Jiajie HeDepartment of Neurosurgery, General Hospital of Northern Theater Command, Postgraduate Training Base of Jinzhou Medical University, Shenyang, China.
Ying XuDepartment of Radiotherapy, General Hospital of Northern Theater Command, Shenyang, China.
Ying YanDepartment of Radiotherapy, General Hospital of Northern Theater Command, Shenyang, China.
Fuyong LiDepartment of Neurosurgery, People's Hospital of Liaoning Province, People's Hospital of China Medical University, Shenyang, China.
Shun GongDepartment of Neurosurgery, General Hospital of Northern Theater Command, Postgraduate Training Base of Dalian Medical University, Shenyang, China.
Jianan LiDepartment of Neurosurgery, General Hospital of Northern Theater Command, Postgraduate Training Base of Dalian Medical University, Shenyang, China.
Peng CaoDepartment of Neurosurgery, General Hospital of Northern Theater Command, Postgraduate Training Base of Dalian Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Intraoperative radiotherapy (IORT) is an emerging local therapy in the surgery of intra-axial brain tumors to improve clinical outcomes and accelerate the adjuvant oncologic therapy. Despite its use in neuro-oncology, the data regarding the role of IORT in the treatment of high-grade gliomas (HGGs) is sparse. Here we reported our single-institutional evidence concerning the efficacy and safety of IORT in the management of HGGs. Methods: A total of thirty patients diagnosed with HGGs who underwent surgical treatment and IORT at our center between October 2021 and October 2023 were included. Clinical data were collected and analyzed, including surgical parameters such as the gross total resection (GTR) rate, follow-up assessments of treatment responses (Karnofsky Performance Status [KPS] scores), treatment-related complications, overall survival (OS), and subsequent therapeutic interventions. Multivariable Cox regression analyses were performed to identify independent risk factors for survival in patients with HGGs. Results: The median IORT dose was 12 Gy prescribed to the applicator surface using the INTRABEAM system. The median OS was 11.0 months (IQR: 7.8-14.3), with a 1-year survival rate of 46.7%. No severe radiation-related adverse events, such as cerebral radiation necrosis or wound-related complications, were recorded. Kaplan-Meier analyses showed that patients who received post-operative radiotherapy and chemotherapy after IORT had better clinical outcomes than those who did not. Multivariable regression analyses indicated post-operative radiotherapy was independently correlated with favorable clinical outcomes. Conclusion: Low-dose X-rays based IORT at doses of 10-12 Gy is generally safe for HGGs. Future prospective large-scale studies are needed to further evaluate the efficacy and safety of IORT with escalating doses. Even with the use of IORT, post-operative radiotherapy is essential for improving clinical outcomes of HGGs. This study provides clinical data on IORT for HGGs, which may represent a promising therapeutic approach for managing this disease.

Indexed as

efficacyhigh-grade gliomasintraoperative radiotherapysafetysurgerysurvival

Identifiers

PMID40391159
PMCPMC12086145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.